×

REGALIA(R) MAXX Biofungicide Receives Registration in Peru

Marrone Bio Innovations logo

DAVIS, Calif., March 31, 2014 (GLOBE NEWSWIRE) -- Marrone Bio Innovations, Inc. (MBI) (Nasdaq:MBII), a leading global provider of bio-based pest management and plant health products, announced FMC, the exclusive Latin America distributor for its REGALIA® MAXX Biofungicide, has received a product registration in Peru. Peru now joins El Salvador, Guatemala, Honduras, Panama and Mexico as Latin America countries having approved the use of REGALIA MAXX to control a wide variety of bacterial and fungal diseases across an array of agricultural crops.

"Peru has been increasing its market share of exported table grapes. But to continue this growth grape producers must meet the guidelines for acceptable pesticide residue levels imposed by importing countries. There is a real market need for REGALIA MAXX which is exempt from maximum residue level restrictions and can help growers manage these requirements," said Luiz Cláudio Micelli, Latin America South Business Director for FMC.

REGALIA MAXX is an advanced biofungicide that can minimize chemical residues by being used alone in a disease-control program, or in rotation with synthetic fungicides or in a tank mix. The product activates a plant's natural defenses to protect against a variety of fungal and bacterial diseases and features multiple modes of action which helps to delay the development of disease resistance. It also provides a four-hour re-entry interval that increases operational flexibility and a zero-day post-harvest interval so crop quality can be protected right up to harvest.

Micelli added, "Armed with REGALIA MAXX, Peruvian grape growers now have a tool to control powdery mildew while reducing synthetic pesticide residues. This is an ideal crop protection solution to help them maintain their high quality standards and advance their export potential, particularly to the U.S. and Europe."

Hector Absi, MBI Chief Operating Officer, commented, "We are excited about our continued registration progress in Latin America and we anticipate strong adoption of REGALIA MAXX in Peru as the product fills a real need for growers of fruit and vegetables earmarked for export."

About Marrone Bio Innovations

Marrone Bio Innovations, Inc. (Nasdaq:MBII) is a leading provider of bio-based pest management and plant health products for the agriculture, turf and ornamental, and water treatment markets. Our effective and environmentally responsible solutions help customers operate more sustainably while controlling pests, improving plant health, and increasing crop yields. We have a proprietary discovery process, a rapid development platform, and a robust pipeline of pest management and plant health product candidates. At Marrone Bio Innovations we are dedicated to pioneering better biopesticides that support a better tomorrow for users around the globe. For more information, please visit www.marronebio.com.

About FMC

FMC Corporation is a diversified chemical company serving agricultural, industrial, environmental, and consumer markets globally for more than a century with innovative solutions, applications and quality products. In 2012, FMC had annual sales of approximately $3.4 billion. The company employs approximately 6,000 people throughout the world, and operates its businesses in three segments: FMC Agricultural Solutions, FMC Health and Nutrition, and FMC Minerals. For more information, visit fmc.com or fmcagricola.com.br

The statements contained in this press release that are not purely historical are forward-looking statements within the meaning of Section 21E of the Securities Exchange Act of 1934, as amended. Forward-looking statements in this press release include statements regarding our expectations, beliefs, hopes, goals, intentions, initiatives or strategies, including statements relating to product use and adoption. Because these forward-looking statements involve risks and uncertainties, there are important factors that could cause actual results to differ materially from those in the forward-looking statements, including the difficulty in predicting the outcome of product research and development efforts and regulatory approvals. Additional relevant information concerning risks can be found in the in the Form 10-Q that the Company filed with the Securities and Exchange Commission on November 8, 2013.

CONTACT: Rich Fedigan Marrone Bio Innovations 530-309-8755 rfedigan@marronebio.com

Source:Marrone Bio Innovations